Get Latest News About Obesity Drug Acomplia (rimonabant) and Diabetes from www.AcompliaReport.com

Acomplia Report (http://www.AcompliaReport.com) editors will provide the latest news about the obesity drug Acomplia (rimonabant) when it is presented at the American Diabetes Association meeting in San Diego.

The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis' application to bring the drug to market.

In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.

Announcement of the results of the RIO-Diabetes trial is slated for a symposium on "Late-Breaking Clinical Trials" set for 2 pm PDT June 12th.

Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier — RIO-North America, RIO-Europe and RIO-Lipids.

The fact that the results are being presented at the highest-profile symposium at the American Diabetes Association meeting — only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators — also strongly suggests more positive news is forthcoming.

News from the presentation will be posted late Sunday on the Acomplia Report (http://www.AcompliaReport.com).

Full coverage of expected news conferences related to the Acomplia (rimonabant) trials will also be posted on the Rimonabant Report (http://www.RimonabantReport.com).

The Acomplia Report (http://www.AcompliaReport.com) and the Rimonabant Report (http://www.RimonabantReport.com) are both published by Medical Week News, Inc., (http://www.MedicalWeek.org), which also publishes Obesity Week (http://www.ObesityWeek.org).